← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Amidebio, Llc
Louisville, CO
$6,817,932
Total funding
4
Grants
Funding over time
peak $1.4M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,817,932 · 4
By mechanism
R44$6,179,544 · 2
R43$638,388 · 2
Investigators at Amidebio, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Long-acting Stable Glucagons for Treatment of Hyperinsulinism$1,405,696
R44 · FY2023 · DK
Long-acting Stable Glucagons for Treatment of Hyperinsulinism$1,287,693
R44 · FY2022 · DK
Dual Agonist Insulins for Treating Diabetics with Impaired Awareness ofHypoglycemia (IAH)$999,468
R44 · FY2025 · DK
Dual Agonist Insulins for Treating Diabetics with Impaired Awareness ofHypoglycemia (IAH)$929,940
R44 · FY2024 · DK
Stable Glucagon for Treatment of Hyperinsulinism$816,607
R44 · FY2020 · DK
Stable Glucagon for Treatment of Hyperinsulinism$740,140
R44 · FY2019 · DK
Stable Glucagon for Treatment of Hyperinsulinism$207,286
R43 · FY2018 · DK
Novel Glucose Responsive Insulin for Improved Treatment of Diabetes$183,955
R43 · FY2021 · DK
Stable Glucagon for Treatment of Hyperinsulinism$131,102
R43 · FY2017 · DK
Novel Glucose Responsive Insulin for Improved Treatment of Diabetes$116,045
R43 · FY2022 · DK